Filtered By:
Infectious Disease: Herpes
Management: Expenditures

This page shows you your search results in order of date.

Order by Relevance | Date

Total 5 results found since Jan 2013.

Factors associated with pneumococcal vaccine uptake among vulnerable older adults in the United States primary care setting
This study assessed factors associated with having gotten a pneumococcal vaccine among vulnerable adults aged 50 and older. This study used the 2018 Medical Expenditure Panel Survey nationally representative dataset. Eligible individuals were aged 50-64 with an 'at risk' health condition or ≥65 years and had a primary care provider as their usual source of care (N = 3,760). Binary logistic regression was used to test factors (identified from literature) for a significant association with getting the pneumococcal vaccine. Factors with significant associations were entered into an adjusted multivariable logistic regression...
Source: Vaccine - October 13, 2022 Category: Allergy & Immunology Authors: Megan Whaley David R Axon Source Type: research

Should we prescribe anticonvulsants for acute herpes zoster neuralgia and to prevent postherpetic neuralgia?: A protocol for meta-analysis and benefit-risk assessment
Background: Herpes zoster-associated pain [i.e., acute herpes zoster neuralgia (AHN) and postherpetic neuralgia (PHN)] has the potential to cause significant patients’ burden and heath resource expenditure. PHN is refractory to the existing treatments, and the consensus is preventing the transition of AHN to PHN is better than treating PHN. Anticonvulsants (e.g., gabapentin, pregabalin) have been recommended as one of the first-line therapies for PHN. In practice, anticonvulsants have also decreased the severity and duration of AHN and reduced the incidence of PHN. Nevertheless, its clinical application to AHN is ham...
Source: Medicine - February 19, 2021 Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research